FDA approves immunotherapy drug combo for non-muscle invasive bladder cancer after UCLA-led research shows improved outcomes for patients

The FDA approval was based on results of the QUILT 3.032 clinical trial, which was led by Dr. Karim Chamie, associate professor urology at the David Geffen School of Medicine at UCLA and a researcher at the UCLA Health Jonsson Comprehensive Cancer Center. 

Read More